Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.8.0.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
During the three months ended March 31, 2018 and 2017, respectively, the Company recognized revenues as follows (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
License fees
$
3,444

 
$
1,008

Research and development services
617

 
335

Other revenues
91

 

Total Revenue
$
4,152

 
$
1,343


During the three months ended March 31, 2018 and 2017, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Three Months Ended March 31,
 
2018
 
2017
Seattle Genetics
$
308

 
$

AstraZeneca
2,545

 

Servier
1,208

 
326

Other
91

 
1,017

Total Revenue
$
4,152

 
$
1,343

Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, Pieris could receive the following potential milestone payments (in millions):
 
Research, Development & Commercial Milestones
 
Sales Milestones
Seattle Genetics
$
769

 
$
450

AstraZeneca
1,111

 
960

Servier
1,069

 
967

Other
353

 
126

Total potential milestone payments
$
3,302

 
$
2,503